8-K Announcements
6Material company update
May 20, 2026·SEC
Material company update
May 13, 2026·SEC
Material company update
Apr 6, 2026·SEC
Inovio Pharmaceuticals, Inc.(INO)Earnings, Financials & Key Ratios
INO•NASDAQ
$1.21
Price updated Jul 7, 2026
AboutInovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.Show more
- Revenue$65K-70.0%
- EBITDA-$84M+23.3%
- Net Income-$85M+20.8%
- EPS (Diluted)-1.81+54.2%
- Gross Margin100%
- EBITDA Margin-128297.25%-155.7%
- Operating Margin-132871.32%-157.4%
- Net Margin-130000%-163.9%
- ROE-183.47%-59.0%
INO Price & Volume
Inovio Pharmaceuticals, Inc. (INO) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Threatens Future Operational Viability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Liquidity and dilution risk
Key Thesis Takeaways
- Inovio Pharmaceuticals faces a precarious outlook as its DNA-based platform remains pre-commercial, resulting in a total revenue collapse to near-zero levels.
- The company's reliance on external capital to fund R&D expenditures exceeding $10 million per quarter has led to severe equity erosion and a reliance on debt.
- Investors should monitor the company's ability to reach clinical milestones, as the current liquidity buffer is insufficient to sustain long-term operations without further dilutive financing.
Verdict Logic
the company's thin equity cushion of only $6.1 million as of 2026Q1 and persistent quarterly cash burn of over $20 million suggest a high risk of further shareholder dilution.
INO Growth Metrics
Inovio Pharmaceuticals, Inc. (INO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-47.43%
5 Years-61.18%
3 Years-81.47%
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM11.97%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM99.89%
Return on Capital
10 Years-82%
5 Years-97.63%
3 Years-114.92%
Last Year-160.02%
INO Recent Earnings
Inovio Pharmaceuticals, Inc. (INO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 3/12 qtrs (50%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.28+6.7%
$0.30
Rev
—
$333,333
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$0.31+183.8%
$0.37
Rev
—
$333,330
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.44+13.7%
$0.51
Rev
—
—
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.61+3.2%
$0.63
Rev
—
$10,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.28vs $0.30+6.7% | —vs $333,333 |
| Q2 2026 | Mar 12, 2026 | $0.31vs $0.37+183.8% | —vs $333,330 |
| Q4 2025 | Nov 10, 2025 | $0.44vs $0.51+13.7% | — |
| Q3 2025 | Aug 12, 2025 | $0.61vs $0.63+3.2% | —vs $10,000 |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Inovio Pharmaceuticals, Inc. (INO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.21 | $836.13M | -0.67 | -69.99% | -130000% | -183.47% | — | |
| $9.46 | $1.56B | 3.72 | 64.69% | -14.73% | — | — | |
| $1.50 | $507.78M | -6.52 | 8.83% | -1605.22% | -127987.5% | — | |
| $15.50 | $1.82B | 77.50 | 19.36% | -13.13% | -8.13% | — | |
| $0.55 | $133.16M | 7.86 | 726.68% | 14.51% | 61.43% | — | |
| $3.50 | $145.75M | -1029.41 | 10.37% | 52.16% | — | — |
Compare INO vs Peers
Inovio Pharmaceuticals, Inc. (INO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
INO SEC Filings & Documents
Inovio Pharmaceuticals, Inc. (INO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when INO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
INO Frequently Asked Questions
Inovio Pharmaceuticals, Inc. (INO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Inovio Pharmaceuticals, Inc.'s revenue?
Inovio Pharmaceuticals, Inc. (INO) reported $0.1M in revenue for fiscal year 2025. This represents a 99% decrease from $8.3M in 1999.
How fast is Inovio Pharmaceuticals, Inc. growing?
Inovio Pharmaceuticals, Inc. (INO) saw revenue decline by 70.0% over the past year.
Is INO profitable?
Inovio Pharmaceuticals, Inc. (INO) reported a net loss of $84.9M for fiscal year 2025.
Dividend & Returns
What is INO's return on equity?
Inovio Pharmaceuticals, Inc. (INO) has a return on equity (ROE) of -183.5%. Negative ROE indicates the company is unprofitable.
What is Inovio Pharmaceuticals, Inc.'s free cash flow?
Inovio Pharmaceuticals, Inc. (INO) had negative free cash flow of $83.6M in fiscal year 2025, likely due to heavy capital investments.